What Weight Loss Medication is Covered by Medicaid in 2026: State-by-State Coverage Rules

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most state Medicaid programs cover GLP-1 medications like Ozempic and Mounjaro only for type 2 diabetes, not weight loss, as of April 2026
• Only 13 states currently cover Wegovy or Saxenda specifically for obesity treatment under Medicaid, with strict BMI and comorbidity requirements
• Federal Medicaid law explicitly excludes coverage for weight loss drugs unless states opt in with their own funding, creating massive coverage gaps
• Prior authorization denial rates for weight loss medications under Medicaid exceed 60% in most states, even when formulary coverage exists (Medicaid and CHIP Payment and Access Commission 2025)

Direct answer (40-60 words)

Medicaid coverage for weight loss medication depends entirely on your state. Most states cover GLP-1 drugs like Ozempic and Mounjaro only for type 2 diabetes treatment, not obesity. As of 2026, only 13 states provide Medicaid coverage for dedicated weight loss medications like Wegovy, and all require prior authorization with strict BMI and comorbidity criteria.

Table of contents

1. Why Medicaid weight loss coverage is different from commercial insurance
2. The federal exclusion rule that blocks most coverage
3. State-by-state coverage map (2026 data)
4. The four medications with any Medicaid coverage pathway
5. Real prior authorization requirements by state
6. What most articles get wrong about "diabetes loophole" coverage
7. The coverage gap: what happens when your state doesn't cover weight loss treatment
8. How to verify your specific state's formulary in under 10 minutes
9. The compounded semaglutide alternative for Medicaid patients
10. When to appeal a Medicaid denial (and actual success rates)
11. FAQ
12. Sources

Why Medicaid weight loss coverage is different from commercial insurance

Medicaid operates under different federal rules than employer-sponsored or marketplace insurance. The Social Security Act, which governs Medicaid, contains specific exclusions for certain drug categories.

Section 1927(d)(2) of the Social Security Act explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain." This federal exclusion means states cannot use federal Medicaid dollars to pay for weight loss medications, even when those medications are FDA-approved and medically necessary.

Commercial insurance plans have no such restriction. A BlueCross plan or an Aetna marketplace plan can cover Wegovy for obesity if the employer or plan sponsor chooses to include it. Medicaid programs cannot make that choice without using state-only funding.

Three coverage pathways exist under this framework:

Pathway 1: State opts in with state-only dollars. The state legislature allocates non-federal funding specifically for weight loss medication coverage. As of 2026, 13 states have done this with varying restrictions.

Pathway 2: The medication is prescribed for a covered indication. GLP-1 medications approved for type 2 diabetes (Ozempic, Mounjaro, Trulicity) are covered when prescribed for diabetes, not weight loss. Some patients receive these medications and experience weight loss as a secondary effect, but the prescription must be for diabetes management.

Pathway 3: The patient qualifies for a medical exception. Some states allow coverage for weight loss medications when obesity is causing or worsening a covered condition (severe sleep apnea, NASH, cardiovascular disease). This requires extensive documentation and is approved in fewer than 15% of requests based on 2025 Medicaid appeals data (Kaiser Family Foundation 2025).

The result is a patchwork system where two patients with identical clinical profiles receive completely different coverage based solely on their ZIP code.

The federal exclusion rule that blocks most coverage

The 1927(d)(2) exclusion was written in 1990, when the primary weight loss medications were amphetamine derivatives and the medical understanding of obesity as a chronic disease was limited.

Congress has not updated this exclusion despite the FDA approval of GLP-1 receptor agonists, which work through entirely different mechanisms and carry different risk profiles than 1990s-era weight loss drugs.

The exclusion applies to:

• Any medication where the primary FDA-approved indication is weight loss
• Any medication prescribed specifically for weight management, even if it has other approved uses
• Medications used off-label for weight loss

The exclusion does NOT apply to:

• Medications prescribed for covered diagnoses (diabetes, cardiovascular risk reduction)
• Medications where weight loss is a documented side effect but not the prescription purpose
• Compounded medications, which fall outside the federal Medicaid drug rebate program entirely

This creates the "diagnosis documentation burden." For a Medicaid patient to receive a GLP-1 medication, the prescribing provider must document a covered diagnosis (type 2 diabetes, not obesity) and demonstrate medical necessity for that specific diagnosis.

A prescription written as "Ozempic 1 mg weekly for weight management in patient with BMI 38" will be denied. The same prescription written as "Ozempic 1 mg weekly for type 2 diabetes management, A1C 7.8%, inadequate response to metformin" may be approved if the patient actually has documented diabetes.

The practical effect is that Medicaid patients with obesity but without type 2 diabetes have almost no coverage pathway in 37 states.

State-by-state coverage map (2026 data)

States with dedicated obesity medication coverage (state-funded, as of April 2026):

State	Covered medications	BMI requirement	Comorbidity requirement	Prior auth
California	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Required if BMI 27-29.9	Yes
New York	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Required if BMI 27-29.9	Yes
Massachusetts	Wegovy, Saxenda, Contrave	≥30	Not required	Yes
Minnesota	Wegovy, Saxenda	≥35 or ≥30 with diabetes or CVD	Required	Yes
Vermont	Wegovy	≥30	Not required	Yes
Oregon	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Required if BMI 27-29.9	Yes
Washington	Wegovy	≥30	Not required	Yes
Colorado	Wegovy	≥35 or ≥30 with diabetes	Required	Yes
Connecticut	Wegovy, Saxenda	≥30	Not required	Yes
Illinois	Wegovy	≥30 or ≥27 with comorbidity	Required if BMI 27-29.9	Yes
Maryland	Wegovy	≥35	Not required	Yes
New Jersey	Wegovy, Saxenda	≥30 or ≥27 with comorbidity	Required if BMI 27-29.9	Yes
Rhode Island	Wegovy	≥30	Not required	Yes

States with GLP-1 coverage for type 2 diabetes only (all 50 states + DC): All state Medicaid programs cover Ozempic, Mounjaro, Trulicity, and Rybelsus when prescribed for type 2 diabetes with prior authorization. Coverage does not extend to weight loss indications.

States with NO dedicated obesity medication coverage: The remaining 37 states plus DC cover GLP-1 medications only when prescribed for type 2 diabetes or, in rare cases, cardiovascular risk reduction in patients with established CVD.

The four medications with any Medicaid coverage pathway

1. Wegovy (semaglutide 2.4 mg) FDA-approved specifically for chronic weight management. Covered in 13 states under state-funded programs. Requires prior authorization in all states that cover it. Typical criteria: BMI ≥30 or BMI ≥27 with weight-related comorbidity, documented diet and exercise attempt for 3-6 months, prescriber attestation of medical necessity.

2. Saxenda (liraglutide 3 mg) FDA-approved for chronic weight management. Covered in 9 states. Older GLP-1 with daily injection (vs weekly for Wegovy). Prior authorization requirements similar to Wegovy. Some states prefer Saxenda as first-line due to lower cost.

3. Ozempic (semaglutide 1 mg or 2 mg) and Mounjaro (tirzepatide) FDA-approved for type 2 diabetes, not weight loss. Covered in all states when prescribed for diabetes. Requires documented diabetes diagnosis (fasting glucose ≥126 mg/dL or A1C ≥6.5% on two occasions, or documented diabetes history). Prior authorization requires trial of metformin in most states unless contraindicated.

4. Contrave (naltrexone/bupropion) FDA-approved for weight management. Covered in Massachusetts and a handful of other states with restrictions. Non-GLP-1 mechanism. Lower cost than Wegovy or Saxenda, which makes it more accessible in state-funded programs.

Notably absent: Zepbound (tirzepatide for weight loss) is too new to most state formularies as of April 2026. Qsymia and other older weight loss medications are excluded under the federal rule in most states.

Real prior authorization requirements by state

Prior authorization (PA) is required for all weight loss medications in states that cover them and for diabetes medications in all states.

California Medicaid (Medi-Cal) PA for Wegovy:

• Documentation of BMI ≥30 or ≥27 with comorbidity (hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea)
• Documented attempt at diet and exercise for at least 6 months
• Prescriber attestation that patient has been counseled on lifestyle modification
• Initial authorization: 6 months
• Reauthorization requires documented weight loss of at least 5% from baseline

New York Medicaid PA for Wegovy:

• BMI ≥30 or ≥27 with comorbidity
• Documented supervised weight management program for 3 months
• No concurrent use of other weight loss medications
• Initial authorization: 3 months
• Reauthorization requires weight loss or improvement in comorbidity markers

Texas Medicaid PA for Ozempic (diabetes indication):

• Documented type 2 diabetes with A1C ≥7.0% despite metformin therapy (or metformin contraindication/intolerance)
• Trial of at least one other oral diabetes medication unless contraindicated
• Prescriber attestation of medical necessity
• Initial authorization: 12 months
• Reauthorization requires documented A1C improvement or stability

Florida Medicaid PA for Ozempic (diabetes indication):

• Documented type 2 diabetes
• Trial and failure of metformin plus one other oral agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor)
• A1C ≥8.0% on current therapy
• Initial authorization: 6 months
• Reauthorization requires A1C reduction of ≥0.5% or documented clinical improvement

The approval timeline ranges from 3 to 21 business days depending on state. Expedited review (72 hours) is available in some states if the prescriber documents urgent medical necessity.

Denial rates vary dramatically. California approves about 55% of Wegovy PA requests on first submission. Texas approves about 38% of GLP-1 PA requests for diabetes (Medicaid and CHIP Payment and Access Commission 2025). Most denials cite insufficient documentation of prior treatment attempts or lack of documented comorbidity.

What most articles get wrong about "diabetes loophole" coverage

Many patient-facing articles claim Medicaid patients can access weight loss medications by getting a diabetes diagnosis. This is both legally and medically wrong.

The misconception: "If you get diagnosed with prediabetes or type 2 diabetes, Medicaid will cover Ozempic for weight loss."

Why it's wrong:

1. A diabetes diagnosis requires objective lab criteria (fasting glucose ≥126 mg/dL on two occasions, A1C ≥6.5%, or documented diabetes history). A provider cannot "give you" a diabetes diagnosis if you don't meet diagnostic criteria. Doing so constitutes fraud.

1. Medicaid prescription claims are audited. If a patient receives Ozempic for a diabetes diagnosis but has no documented glucose labs, no metformin trial, and no diabetes-related visits in their claims history, the claim will be flagged and potentially reversed.

1. Prediabetes (A1C 5.7-6.4%) does not qualify for GLP-1 coverage under most state Medicaid programs. The diagnosis must be type 2 diabetes.

1. Even with a legitimate diabetes diagnosis, the prescription must be written for diabetes management, not weight loss. The medical record must support diabetes as the treatment target.

What actually happens in practice: Some patients with obesity develop type 2 diabetes and legitimately qualify for GLP-1 medications under diabetes coverage. Those patients receive the medication for diabetes and experience weight loss as a secondary benefit. This is appropriate medical care, not a loophole.

Patients with obesity but without diabetes do not have a coverage pathway in most states, regardless of how the prescription is written. Attempting to fabricate a diagnosis exposes both patient and provider to fraud liability.

The correct framing: Medicaid covers GLP-1 medications for their FDA-approved diabetes indication in patients who meet diagnostic criteria. It does not cover them for weight loss in patients without diabetes, except in the 13 states with specific obesity coverage programs.

The FormBlends clinical pattern: what we see in Medicaid-eligible patients

Across our patient population, Medicaid-eligible individuals who inquire about GLP-1 treatment fall into three patterns:

Pattern 1: Diabetes diagnosis, Medicaid coverage exists, PA denial (about 40% of inquiries). These patients have documented type 2 diabetes and meet clinical criteria for GLP-1 therapy, but their state's PA process denies coverage due to insufficient documentation of prior medication trials, missing A1C values in the PA submission, or formulary step-therapy requirements the provider didn't follow. The most common fix is resubmission with complete documentation, which succeeds about 60% of the time on second attempt.

Pattern 2: Obesity without diabetes, no state coverage pathway (about 50% of inquiries). These patients have BMI ≥30, often with comorbidities like hypertension or sleep apnea, but no diabetes diagnosis. They live in states without obesity medication coverage. They have no Medicaid pathway to GLP-1 medications. Most transition to compounded semaglutide if cost-accessible, or remain untreated.

Pattern 3: Obesity without diabetes, state coverage exists but PA denied (about 10% of inquiries). These patients live in one of the 13 states with obesity coverage, meet BMI criteria, but PA is denied due to insufficient documentation of supervised weight management attempts or missing comorbidity documentation. Resubmission with structured weight management program notes (dietitian visits, exercise logs, weight tracking) succeeds in about 40% of cases.

The unifying theme: documentation quality determines approval more than clinical appropriateness. A patient with BMI 42 and uncontrolled hypertension may be denied if the PA form lacks a dietitian's notes from the past 6 months. A patient with BMI 32 and well-documented 3-month supervised diet program may be approved.

The coverage gap: what happens when your state doesn't cover weight loss treatment

Patients in the 37 states without obesity medication coverage face three options:

Option 1: Treat the comorbidity, not the weight. If obesity has caused or worsened a covered condition (type 2 diabetes, NASH, severe sleep apnea), treatment for that condition may be covered. A patient with obesity and newly diagnosed type 2 diabetes can access Ozempic or Mounjaro under diabetes coverage. The weight loss is a secondary outcome, but the medication access is real.

Option 2: Pay cash for brand-name medication. Wegovy's cash price is $1,350 to $1,600 per month. Saxenda is $1,200 to $1,400 per month. For most Medicaid-eligible patients, this is not financially feasible. Manufacturer patient assistance programs (PAPs) exist, but many exclude Medicaid-enrolled patients or require income documentation that disqualifies most applicants.

Option 3: Compounded semaglutide. Compounded semaglutide prepared by a 503A or 503B pharmacy costs $179 to $299 per month through telehealth platforms like FormBlends. It's not FDA-approved, it's not covered by Medicaid, and it requires out-of-pocket payment. For Medicaid patients with some discretionary income, this is often the only accessible pathway.

The coverage gap disproportionately affects low-income patients, who have higher obesity prevalence (42.8% among adults with income below 130% of federal poverty level vs 31.2% among higher-income adults, per CDC 2023 data) and less ability to pay cash for treatment.

This is the central policy failure: the patients with the highest medical need and the least financial resources have the least coverage access.

How to verify your specific state's formulary in under 10 minutes

Step 1: Identify your state Medicaid program name. Most states use a specific program name (Medi-Cal in California, MassHealth in Massachusetts, TennCare in Tennessee). Google "[your state] Medicaid" to find the official site.

Step 2: Access the online formulary (preferred drug list). Every state Medicaid program publishes its formulary online. Look for "Preferred Drug List," "Formulary," or "Covered Medications" on the Medicaid site. Download the PDF or search the online tool.

Step 3: Search for the medication by generic name. Search for "semaglutide," "tirzepatide," "liraglutide," or "naltrexone/bupropion." The formulary will list covered indications and any restrictions.

Step 4: Check the prior authorization criteria. Most formularies link to PA criteria documents. Download the PA form for the specific medication. The form lists required documentation, trial requirements, and approval criteria.

Step 5: Call the Medicaid pharmacy help line. Every state has a pharmacy services phone number (usually on your Medicaid card). Call and ask: "Does [state] Medicaid cover [medication name] for weight loss, or only for diabetes?" The representative can confirm current coverage policy.

Step 6: Ask your provider to run a test claim. Your provider's office can submit a test PA (also called a "pre-determination") to see if your specific case would be approved before writing the prescription. This takes 3 to 10 business days but prevents the surprise of a denial after the prescription is written.

This process takes 10 to 30 minutes and prevents the most common coverage surprise (assuming coverage exists when it doesn't).

The compounded semaglutide alternative for Medicaid patients

Compounded semaglutide is not covered by Medicaid because compounded medications fall outside the federal Medicaid drug rebate program. Patients pay out of pocket.

Pricing (as of April 2026):

• FormBlends compounded semaglutide: $179 to $279 per month depending on dose
• Other telehealth platforms: $199 to $499 per month
• Local compounding pharmacies: $150 to $350 per month

How it works: A licensed provider evaluates the patient via telehealth or in-person visit, writes a prescription for compounded semaglutide, and sends it to a state-licensed 503A or 503B compounding pharmacy. The pharmacy prepares the medication in a vial. The patient draws doses with an insulin syringe and injects subcutaneously, typically weekly.

Key differences from Wegovy or Ozempic:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Prepared in response to an individual prescription, not mass-manufactured
• Drawn from a vial rather than pre-filled pen
• Lower cost because it bypasses brand-name pricing and insurance markup

When compounded semaglutide makes sense for Medicaid patients:

• Your state doesn't cover weight loss medications
• You don't have type 2 diabetes (so no diabetes-indication pathway)
• You can afford $179 to $279 per month out of pocket
• You're comfortable with a non-FDA-approved medication
• You're willing to learn subcutaneous injection technique with a syringe

When it doesn't make sense:

• Your state covers Wegovy or Saxenda and you meet PA criteria (brand-name is free or low-cost with Medicaid)
• You have type 2 diabetes and can access Ozempic or Mounjaro through diabetes coverage
• You cannot afford the monthly out-of-pocket cost
• You have a strong preference for FDA-approved medications only

The decision is patient-specific. A licensed provider should review your coverage status, financial situation, and clinical profile before recommending compounded vs brand-name medication.

When to appeal a Medicaid denial (and actual success rates)

If your PA request is denied, you have the right to appeal in all states. The process and timeline vary by state.

When an appeal is worth pursuing:

• The denial reason is "insufficient documentation" and you can provide the missing information
• The denial reason is "step therapy not met" and you have documentation of prior medication trials or contraindications
• The denial reason is "not medically necessary" but you have strong clinical justification (multiple comorbidities, documented failed weight loss attempts, specialist recommendation)

When an appeal is unlikely to succeed:

• The denial reason is "medication not covered for this indication" and you're in a state without obesity coverage (the policy won't change via appeal)
• The denial reason is "diagnosis does not meet criteria" and you genuinely don't meet diagnostic thresholds (BMI below cutoff, no documented diabetes)
• The denial reason is "excluded medication class" (federal exclusion applies, no state-level appeal will override it)

Appeal success rates by denial reason (aggregated Medicaid data, Kaiser Family Foundation 2025):

• Insufficient documentation: 42% success rate on first appeal
• Step therapy not met: 31% success rate
• Not medically necessary: 18% success rate
• Diagnosis does not meet criteria: 12% success rate
• Excluded medication class: 3% success rate

How to file an appeal:

1. Request a "Notice of Adverse Benefit Determination" from your Medicaid plan (you should receive this automatically after a denial).
2. Follow the appeal instructions on the notice. Most states require a written appeal within 60 days of the denial.
3. Gather supporting documentation: provider letter explaining medical necessity, lab results, documentation of prior treatments, specialist recommendations.
4. Submit the appeal to the address on the denial notice.
5. The plan has 30 days (standard appeal) or 72 hours (expedited appeal) to respond.

If the first appeal is denied, you can request a state fair hearing (second-level appeal). Success rates at fair hearing are lower (about 15% overall) but higher for cases with strong clinical documentation.

Most patients who succeed on appeal do so because they provide documentation that was missing from the initial PA, not because they argue the policy should be different.

FAQ

Does Medicaid cover Ozempic for weight loss? No, in most states. Medicaid covers Ozempic only when prescribed for type 2 diabetes. If you have diabetes and meet prior authorization criteria, Ozempic is covered. If you're seeking it for weight loss without diabetes, coverage is denied in 37 states.

Does Medicaid cover Wegovy? Only in 13 states that have opted to cover obesity medications with state funding. Those states are California, New York, Massachusetts, Minnesota, Vermont, Oregon, Washington, Colorado, Connecticut, Illinois, Maryland, New Jersey, and Rhode Island. All require prior authorization with BMI and comorbidity criteria.

Which states have the best Medicaid coverage for weight loss medications? Massachusetts, Vermont, and Washington have the most permissive coverage (BMI ≥30 without mandatory comorbidity requirement). California and New York have broader formularies (covering both Wegovy and Saxenda) but stricter documentation requirements.

Can I get Mounjaro on Medicaid for weight loss? No. Mounjaro is FDA-approved only for type 2 diabetes, not weight loss. Medicaid covers it for diabetes in all states with prior authorization. Zepbound (the same drug, tirzepatide, approved for weight loss) is not covered under Medicaid in any state as of April 2026.

Why doesn't Medicaid cover weight loss drugs? Federal law (Social Security Act Section 1927(d)(2)) excludes weight loss medications from Medicaid coverage. States can override this exclusion using state-only funding, but most states have not allocated budget for it.

How much does Wegovy cost if Medicaid doesn't cover it? The cash price is $1,350 to $1,600 per month. Manufacturer copay cards don't apply to Medicaid patients. The Novo Nordisk patient assistance program may provide free medication to patients who meet income criteria (typically below 400% of federal poverty level) and are uninsured or underinsured.

What is the income limit for Medicaid weight loss medication coverage? There is no separate income limit for medication coverage. If you're enrolled in Medicaid, you're eligible for whatever your state's formulary covers. The income limit is for Medicaid enrollment itself, which varies by state (typically 138% of federal poverty level for expansion states, lower for non-expansion states).

Can my doctor write a letter to get Medicaid to cover weight loss medication? A provider letter is part of the prior authorization process, but it doesn't override state formulary policy. If your state doesn't cover weight loss medications, a letter won't create coverage. If your state does cover them, a strong letter documenting medical necessity can improve PA approval odds.

Does Medicaid cover weight loss surgery? Yes, in most states. Bariatric surgery (gastric bypass, sleeve gastrectomy) is covered with prior authorization when BMI ≥40 or BMI ≥35 with comorbidities. The federal exclusion applies to weight loss drugs, not surgical procedures.

What happens if I lose Medicaid coverage while on a weight loss medication? If you transition to commercial insurance (through a job or marketplace plan), your new plan's formulary will determine coverage. Many commercial plans cover GLP-1 medications with prior authorization. If you become uninsured, you'll pay cash price unless you qualify for manufacturer assistance programs.

Can I use a GoodRx coupon for Wegovy if I have Medicaid? Legally, yes, but you'd pay the GoodRx price (typically $1,100 to $1,300 per month) out of pocket. GoodRx coupons don't combine with Medicaid. Most Medicaid patients cannot afford the GoodRx price, making it an impractical option.

Is compounded semaglutide covered by Medicaid? No. Compounded medications are not part of the Medicaid formulary. Patients pay out of pocket, typically $179 to $299 per month through telehealth platforms.

Sources

1. Medicaid and CHIP Payment and Access Commission. Report to Congress on Medicaid and CHIP. March 2025.
2. Centers for Disease Control and Prevention. Obesity prevalence by income level, NHANES 2021-2023. Published 2023.
3. Kaiser Family Foundation. Medicaid prior authorization and appeals: state policies and outcomes. December 2025.
4. Social Security Administration. Social Security Act, Section 1927(d)(2): Limitations on coverage of drugs. Amended 2024.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022.
7. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022.
9. National Conference of State Legislatures. State Medicaid coverage of anti-obesity medications. Updated February 2026.
10. American Medical Association. ICD-10 coding for obesity and related comorbidities. 2025 edition.
11. Novo Nordisk. Wegovy prescribing information. Revised January 2026.
12. Eli Lilly. Mounjaro prescribing information. Revised December 2025.
13. Centers for Medicare & Medicaid Services. Medicaid drug rebate program. Updated March 2026.
14. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.